

Technical Data Sheet

Biotin Human EphA2 Protein (C-His-Avi)

Catalog Number: 814303, 814304

Size: 25 ug, 100 ug

Target Name: EphA2

Regulatory Status: RUO

Product Details

Application: ELISA, BLI

Format: Liquid, Biotinylated

Expression Host: CHO

Species: Human

Sources: Recombinant Human EphA2 (Gln25-Asn534) with C-terminus His-Avi-tag is expressed in CHO cell. This protein was site-specifically labeled with Biotin by BirA ligase.

Accession Number: P29317

Molecular Weight: The protein has a predicted molecular weight of 59.7 kDa. Under DTT-reducing conditions, it migrates at approximately 65 kDa on SDS-PAGE.

Affinity Tag: C-His-Avi

Purity: >95% based on SDS-PAGE under reducing condition

Formulation: 1xPBS buffer, pH7.4, 0.22 µm filtered

Endotoxin level: Not tested

Protein Concentration: 25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.


Storage and Handling: Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ -70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.

Background Information

EphA2 (Ephrin type-A receptor 2) is a receptor tyrosine kinase involved in cell adhesion, migration, and tissue organization. It plays a critical role in embryonic development and angiogenesis. EphA2 is frequently overexpressed in various cancers, including breast, lung, and prostate cancer.

Overexpression is associated with increased tumor growth, invasiveness, and poor clinical outcomes. Because of its role in promoting tumor progression, EphA2 is being actively explored as a therapeutic target in oncology. Therapeutic strategies include monoclonal antibodies, small molecule inhibitors, and antibody-drug conjugates targeting EphA2-positive tumors.

Product Data



Human EphA2 Protein (C-His-Avi) was biotinylated in vitro using BirA ligase. SDS-PAGE analysis under reducing (P+) and non-reducing (P-) conditions shows the protein has a purity greater than 95%. A gel shift assay using co-incubation with streptavidin indicates that the biotinylation efficiency of Human EphA2 protein exceeds 80%.